Health & Environmental Research Online (HERO)


Print Feedback Export to File
538841 
Journal Article 
Drug-induced thrombotic microangiopathy 
Zakarija, A; Bennett, C 
2005 
1 
Seminars in Thrombosis and Hemostasis
ISSN: 0094-6176
EISSN: 1098-9064 
31 
6 
681-690 
English 
Drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome (TTP/HUS) has been recognized for several years. The most commonly implicated drugs are mitomycin-C, cyclosporine, quinine, and ticlopidine. As with idiopathic cases of TTP/HUS, basic science discoveries in the late 1990s now suggest that the likely mechanisms by which these agents lead to a thrombotic microangiopathy (TMA) include either an immune-mediated phenomenon involving the ADAMTS13 metalloprotease or direct endothelial toxicity. This article reviews the current understanding of the pathogenesis, the clinical and laboratory features, and the recommended treatments, prognosis, and outcomes of drug-associated TMA. 
thrombotic microangiopathy; thrombotic thrombocytopenic purpura; hemolytic uremic syndrome; drug toxicity; hemolytic-uremic syndrome; von-willebrand-factor; factor-cleaving; protease; bone-marrow-transplantation; induced immune thrombocytopenia; of-the-literature; cyclosporine-a; mitomycin-c; interferon therapy; renal-allografts